MX2024005996A - Inhibidor de kif18a. - Google Patents
Inhibidor de kif18a.Info
- Publication number
- MX2024005996A MX2024005996A MX2024005996A MX2024005996A MX2024005996A MX 2024005996 A MX2024005996 A MX 2024005996A MX 2024005996 A MX2024005996 A MX 2024005996A MX 2024005996 A MX2024005996 A MX 2024005996A MX 2024005996 A MX2024005996 A MX 2024005996A
- Authority
- MX
- Mexico
- Prior art keywords
- kif18a
- inhibitor
- preparation
- compound represented
- general formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111399876 | 2021-11-19 | ||
| CN202210225663 | 2022-03-09 | ||
| CN202210667619 | 2022-06-13 | ||
| PCT/CN2022/132954 WO2023088441A1 (zh) | 2021-11-19 | 2022-11-18 | Kif18a抑制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005996A true MX2024005996A (es) | 2024-05-30 |
Family
ID=86396297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005996A MX2024005996A (es) | 2021-11-19 | 2022-11-18 | Inhibidor de kif18a. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4434979A4 (https=) |
| JP (1) | JP2024542199A (https=) |
| KR (1) | KR20240108489A (https=) |
| CN (1) | CN118215657A (https=) |
| AU (1) | AU2022389558A1 (https=) |
| CA (1) | CA3237625A1 (https=) |
| MX (1) | MX2024005996A (https=) |
| WO (1) | WO2023088441A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI844602B (zh) | 2018-12-20 | 2024-06-11 | 美商安進公司 | Kif18a抑制劑 |
| CN119241504A (zh) | 2021-08-26 | 2025-01-03 | 沃拉斯查疗法公司 | Kif18a的螺吲哚啉抑制剂 |
| WO2024022508A1 (zh) * | 2022-07-29 | 2024-02-01 | 武汉人福创新药物研发中心有限公司 | Kif18a抑制剂及用途 |
| TW202416973A (zh) | 2022-08-18 | 2024-05-01 | 美商雅客森醫療公司 | Ｋｉｆ１８ａ抑制劑及其用途 |
| CN117917405A (zh) * | 2022-10-21 | 2024-04-23 | 杭州邦顺制药有限公司 | Kif18a蛋白抑制剂 |
| CN120202002A (zh) * | 2022-11-30 | 2025-06-24 | 微境生物医药科技(上海)有限公司 | 一种用于癌症治疗的药物组合物 |
| EP4628486A1 (en) * | 2022-12-02 | 2025-10-08 | Shenzhen Zhongge Biological Technology Co., Ltd. | Amide or urea compound |
| WO2024146593A1 (zh) * | 2023-01-05 | 2024-07-11 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物及其制备方法和医药上的用途 |
| WO2024244972A1 (zh) * | 2023-05-30 | 2024-12-05 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物及其制备方法和用途 |
| CN121532380A (zh) * | 2023-07-21 | 2026-02-13 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物及其制备方法和用途 |
| WO2025026392A1 (zh) * | 2023-08-02 | 2025-02-06 | 上海湃隆生物科技有限公司 | 驱动蛋白kif18a抑制剂及其应用 |
| WO2025036479A1 (zh) * | 2023-08-16 | 2025-02-20 | 上海湃隆生物科技有限公司 | 驱动蛋白kif18a抑制剂及其应用 |
| WO2025190888A1 (en) * | 2024-03-12 | 2025-09-18 | F. Hoffmann-La Roche Ag | Macrocyclic kif18a inhibitors and their use thereof |
| TW202547479A (zh) * | 2024-03-27 | 2025-12-16 | 大陸商上海齊魯製藥研究中心有限公司 | 驅動蛋白kif18a抑制劑及其使用方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO395396A0 (en) * | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| WO2020132651A1 (en) * | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| EP3898616B1 (en) * | 2018-12-20 | 2024-10-02 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| TWI844602B (zh) | 2018-12-20 | 2024-06-11 | 美商安進公司 | Kif18a抑制劑 |
| JP7676308B2 (ja) * | 2018-12-20 | 2025-05-14 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド |
| US12540129B2 (en) * | 2019-08-02 | 2026-02-03 | Amgen Inc. | KIF18A inhibitors |
| AU2020326627B2 (en) * | 2019-08-02 | 2026-01-29 | Amgen Inc. | KIF18A inhibitors |
| WO2021026099A1 (en) * | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| JP2023521802A (ja) * | 2020-04-14 | 2023-05-25 | アムジエン・インコーポレーテツド | 新生物疾患の処置のためのｋｉｆ１８ａ阻害剤 |
| JP2024534572A (ja) * | 2021-09-24 | 2024-09-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ナトリウムチャンネル活性化剤としてのピリジニルアセトアミド誘導体 |
-
2022
- 2022-11-18 AU AU2022389558A patent/AU2022389558A1/en active Pending
- 2022-11-18 JP JP2024529504A patent/JP2024542199A/ja active Pending
- 2022-11-18 EP EP22894970.7A patent/EP4434979A4/en active Pending
- 2022-11-18 CA CA3237625A patent/CA3237625A1/en active Pending
- 2022-11-18 KR KR1020247020178A patent/KR20240108489A/ko active Pending
- 2022-11-18 MX MX2024005996A patent/MX2024005996A/es unknown
- 2022-11-18 CN CN202280076424.9A patent/CN118215657A/zh active Pending
- 2022-11-18 WO PCT/CN2022/132954 patent/WO2023088441A1/zh not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4434979A4 (en) | 2025-10-29 |
| KR20240108489A (ko) | 2024-07-09 |
| CN118215657A (zh) | 2024-06-18 |
| CA3237625A1 (en) | 2023-05-25 |
| EP4434979A1 (en) | 2024-09-25 |
| WO2023088441A1 (zh) | 2023-05-25 |
| AU2022389558A1 (en) | 2024-05-23 |
| JP2024542199A (ja) | 2024-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024005996A (es) | Inhibidor de kif18a. | |
| MX2023012361A (es) | Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo. | |
| MX2021013981A (es) | Inhibidores de la cinasa aurora y usos de los mismos. | |
| NZ766978A (en) | Atr inhibitor and application thereof | |
| MX2022006608A (es) | Nuevos inhibidores de aurora cinasa y uso de los mismos. | |
| SA521422143B1 (ar) | 15-pgdh مثبط | |
| ZA202206923B (en) | New methylquinazolinone derivatives | |
| JOP20200336A1 (ar) | طرق إعطاء مثبطات vmat2 معينة | |
| ZA202206481B (en) | Amide derivative and preparation method therefore and use thereof in medicine | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| PH12022551104A1 (en) | Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof | |
| ZA202400988B (en) | Aak1 inhibitor and use thereof | |
| ZA202407806B (en) | Kif18a inhibitor and use thereof | |
| CA2665931C (en) | Hydrobenzamide derivatives as inhibitors of hsp90 | |
| PH12020552244A1 (en) | Heterocyclic compounds as trk inhibitors | |
| AU2020288567A8 (en) | Pyrrolopyrimidine compound and use thereof | |
| MX2009010302A (es) | Derivados de indol que tienen actividad inhibidora de cpla2 y aplicaciones y metodos de produccion. | |
| MX2025007797A (es) | Derivado de tetrahidrotiofeno y uso de este en medicina | |
| CR20220255A (es) | Inhibidores de egfr | |
| MX389786B (es) | Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer. | |
| MX2021003686A (es) | Medicamento para el tratamiento de la tos cronica. | |
| MX2021003232A (es) | Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa. | |
| MX2025013601A (es) | Inhibidor selectivo de hdac1/2 y uso de este | |
| MX2025000403A (es) | Compuestos como inhibidores de myt1 | |
| SG170796A1 (en) | Methods for improving the pharmacokinetics of hiv integrase inhibitors |